Skeletal muscle metabolism limits exercise capacity in patients with chronic heart failure. 1998

K Okita, and K Yonezawa, and H Nishijima, and A Hanada, and M Ohtsubo, and T Kohya, and T Murakami, and A Kitabatake
Department of Cardiovascular Medicine, Hokkaido University School of Medicine, and the Sapporo Health Promotion Center, Sapporo, Japan.

BACKGROUND Several studies have indicated that skeletal muscle is important in determining the exercise capacity of patients with chronic heart failure (CHF). However, this theory has been investigated only in experiments based on local exercise involving a small muscle mass. We investigated skeletal muscle metabolism during maximal systemic exercise to determine whether muscle metabolism limits exercise capacity in patients with CHF. We also studied the relationship between muscle metabolic abnormalities during local and systemic exercise. RESULTS Skeletal muscle metabolism was measured during maximal systemic exercise on a bicycle ergometer by a combination of the metabolic freeze method and 31P magnetic resonance spectroscopy in 12 patients with CHF and 7 age- and size-matched normal subjects. We also evaluated skeletal muscle metabolism during local exercise while subjects performed unilateral plantar flexion. Muscle phosphocreatine (PCr) was nearly depleted during maximal systemic exercise in patients with CHF and normal subjects (12.5+/-0.04% and 12.3+/-0.07%, respectively, of initial level). PCr depletion occurred at a significantly lower peak oxygen uptake (peak VO2) in patients with CHF than in normal subjects (CHF, 20.2+/-3.0 versus normal, 31.8+/-3.7 mL . min-1 . kg-1, P<0. 0001). Muscle metabolic capacity, evaluated as the slope of PCr decrease in relation to increasing workload, was correlated with peak VO2 during maximal systemic exercise in patients with CHF (r=0.83, P<0.001). Muscle metabolic capacity during local exercise was impaired in patients with CHF and was correlated with capacity during systemic exercise (r=0.76, P<0.01) and with peak VO2 (r=0. 83, P<0.001). CONCLUSIONS These results suggest that impaired muscle metabolism associated with early metabolic limitation determines exercise capacity during maximal systemic exercise in patients with CHF. There was a significant correlation between muscle metabolic capacity during systemic and local exercise in patients with CHF.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009682 Magnetic Resonance Spectroscopy Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING). In Vivo NMR Spectroscopy,MR Spectroscopy,Magnetic Resonance,NMR Spectroscopy,NMR Spectroscopy, In Vivo,Nuclear Magnetic Resonance,Spectroscopy, Magnetic Resonance,Spectroscopy, NMR,Spectroscopy, Nuclear Magnetic Resonance,Magnetic Resonance Spectroscopies,Magnetic Resonance, Nuclear,NMR Spectroscopies,Resonance Spectroscopy, Magnetic,Resonance, Magnetic,Resonance, Nuclear Magnetic,Spectroscopies, NMR,Spectroscopy, MR
D010725 Phosphocreatine An endogenous substance found mainly in skeletal muscle of vertebrates. It has been tried in the treatment of cardiac disorders and has been added to cardioplegic solutions. (Reynolds JEF(Ed): Martindale: The Extra Pharmacopoeia (electronic version). Micromedex, Inc, Englewood, CO, 1996) Creatine Phosphate,Neoton,Phosphocreatine, Disodium Salt,Phosphorylcreatine,Disodium Salt Phosphocreatine,Phosphate, Creatine
D010807 Physical Endurance The time span between the beginning of physical activity by an individual and the termination because of exhaustion. Endurance, Physical,Physical Stamina,Stamina, Physical
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D002303 Cardiac Output, Low A state of subnormal or depressed cardiac output at rest or during stress. It is a characteristic of CARDIOVASCULAR DISEASES, including congenital, valvular, rheumatic, hypertensive, coronary, and cardiomyopathic. The serious form of low cardiac output is characterized by marked reduction in STROKE VOLUME, and systemic vasoconstriction resulting in cold, pale, and sometimes cyanotic extremities. Low Cardiac Output,Low Cardiac Output Syndrome,Output, Low Cardiac
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

K Okita, and K Yonezawa, and H Nishijima, and A Hanada, and M Ohtsubo, and T Kohya, and T Murakami, and A Kitabatake
July 1996, Heart (British Cardiac Society),
K Okita, and K Yonezawa, and H Nishijima, and A Hanada, and M Ohtsubo, and T Kohya, and T Murakami, and A Kitabatake
April 2006, The Canadian journal of cardiology,
K Okita, and K Yonezawa, and H Nishijima, and A Hanada, and M Ohtsubo, and T Kohya, and T Murakami, and A Kitabatake
January 2003, Congestive heart failure (Greenwich, Conn.),
K Okita, and K Yonezawa, and H Nishijima, and A Hanada, and M Ohtsubo, and T Kohya, and T Murakami, and A Kitabatake
March 1996, Clinical physiology (Oxford, England),
K Okita, and K Yonezawa, and H Nishijima, and A Hanada, and M Ohtsubo, and T Kohya, and T Murakami, and A Kitabatake
March 2018, Circulation journal : official journal of the Japanese Circulation Society,
K Okita, and K Yonezawa, and H Nishijima, and A Hanada, and M Ohtsubo, and T Kohya, and T Murakami, and A Kitabatake
April 1993, Journal of the American College of Cardiology,
K Okita, and K Yonezawa, and H Nishijima, and A Hanada, and M Ohtsubo, and T Kohya, and T Murakami, and A Kitabatake
April 2001, Medicine and science in sports and exercise,
K Okita, and K Yonezawa, and H Nishijima, and A Hanada, and M Ohtsubo, and T Kohya, and T Murakami, and A Kitabatake
May 1990, Clinical science (London, England : 1979),
K Okita, and K Yonezawa, and H Nishijima, and A Hanada, and M Ohtsubo, and T Kohya, and T Murakami, and A Kitabatake
September 1995, Journal of cardiac failure,
K Okita, and K Yonezawa, and H Nishijima, and A Hanada, and M Ohtsubo, and T Kohya, and T Murakami, and A Kitabatake
May 2008, Basic research in cardiology,
Copied contents to your clipboard!